Assessment of early cytogenetic response by 3 months versus >3-6 months or no response by 6 months as a predictor of long-term clinical outcomes in a phase 1/2 study of bosutinib in chronic phase cml

Authors
Category Primary study
JournalBlood
Year 2013
This article has no abstract
Epistemonikos ID: c5c67f23e115b5224ac87384a2bf683e5080d68b
First added on: Feb 05, 2025